|
End-of-day quote
Nasdaq
2026-09-04
|
5-day change | 1st Jan Change | ||
| 1.820 USD | -0.55% |
|
-1.89% | -79.84% |
| 09-08 | EnGene Therapeutics Inc. Provides Clinical Updates | CI |
| 09-08 | EnGene Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026 | CI |
Company Valuation: enGene Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: October | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | - | 451.1 | 369.1 | 128.6 | - | - |
| Change | - | - | -18.18% | -65.15% | - | - |
| Enterprise Value (EV) 1 | - | 236 | 190.7 | -82.63 | -18.01 | -10.69 |
| Change | - | - | -19.19% | -143.33% | 78.21% | 40.67% |
| P/E | -0.14x | -6.06x | -3.15x | -1.05x | -1.23x | -1.65x |
| PBR | - | 1.65x | 2.2x | 0.71x | 1.15x | 1.48x |
| PEG | - | 0.1x | -0.1x | 0.1x | 0.1x | 0.1x |
| Capitalization / Revenue | - | - | - | - | 18.2x | 3.56x |
| EV / Revenue | - | - | - | - | -2.55x | -0.3x |
| EV / EBITDA | - | -3.81x | -1.55x | 0.65x | 0.17x | 0.09x |
| EV / EBIT | - | -3.79x | -1.55x | 0.63x | 0.15x | 0.08x |
| EV / FCF | - | - | -1.89x | 0.6x | 0.12x | 0.07x |
| FCF Yield | - | - | -52.8% | 167% | 837% | 1,362% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -151.2 | -1.46 | -2.29 | -1.831 | -1.558 | -1.165 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | 7.052 | 36.1 |
| EBITDA 1 | - | -61.97 | -122.7 | -127.4 | -106.7 | -121.4 |
| EBIT 1 | - | -62.3 | -123.2 | -130.7 | -123.1 | -126.5 |
| Net income 1 | -99.92 | -55.14 | -117.3 | -125.9 | -121.9 | -125.1 |
| Net Debt 1 | - | -215.2 | -178.4 | -211.3 | -146.6 | -139.3 |
| Reference price 2 | 21.695 | 8.850 | 7.210 | 1.920 | 1.920 | 1.920 |
| Nbr of stocks (in thousands) | - | 50,974 | 51,192 | 66,989 | - | - |
| Announcement Date | 1/29/24 | 12/19/24 | 12/22/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.04x | - | 0.69x | -.--% | 122M | |
| 19.9x | 7.03x | 14.13x | 1.49% | 67.82B | |
| 35.92x | 9.37x | 28.59x | 0.04% | 63.22B | |
| -77.3x | 14.92x | -71.95x | -.--% | 27.58B | |
| -15.84x | 6.12x | -7.7x | -.--% | 26.06B | |
| 29.27x | 6.25x | 16.23x | -.--% | 25.38B | |
| 27.11x | 5.08x | 16.9x | -.--% | 19.89B | |
| 49.98x | 18.45x | 37.42x | 0.3% | 17.4B | |
| 1291.85x | 37.31x | 814.25x | -.--% | 14.95B | |
| 18.23x | 5.44x | 12.69x | -.--% | 14.62B | |
| Average | 137.81x | 12.22x | 86.13x | 0.18% | 27.71B | |
| Weighted average by Cap. | 82.33x | 10.32x | 51.76x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ENGN Stock
- Valuation enGene Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
